Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC boosted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERAFree Report) by 25.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 170,758 shares of the company’s stock after acquiring an additional 34,381 shares during the period. Rafferty Asset Management LLC owned about 0.33% of Vera Therapeutics worth $2,626,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Amalgamated Bank grew its holdings in Vera Therapeutics by 26.0% during the 3rd quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock worth $57,000 after acquiring an additional 864 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Vera Therapeutics during the 4th quarter worth approximately $79,000. SG Americas Securities LLC purchased a new stake in shares of Vera Therapeutics during the 4th quarter worth approximately $119,000. New York State Common Retirement Fund lifted its position in shares of Vera Therapeutics by 55.5% during the 4th quarter. New York State Common Retirement Fund now owns 17,491 shares of the company’s stock worth $269,000 after buying an additional 6,244 shares during the last quarter. Finally, Profund Advisors LLC purchased a new stake in shares of Vera Therapeutics during the 3rd quarter worth approximately $317,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VERA. Guggenheim restated a “buy” rating and set a $56.00 price objective on shares of Vera Therapeutics in a research report on Friday, April 5th. JPMorgan Chase & Co. boosted their price objective on shares of Vera Therapeutics from $60.00 to $65.00 and gave the stock an “overweight” rating in a research report on Friday, May 31st. Raymond James boosted their price objective on shares of Vera Therapeutics from $57.00 to $68.00 and gave the stock a “strong-buy” rating in a research report on Friday, May 10th. Finally, Wedbush boosted their price objective on shares of Vera Therapeutics from $21.00 to $34.00 and gave the stock a “neutral” rating in a research report on Thursday, March 21st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $42.86.

Read Our Latest Report on Vera Therapeutics

Insiders Place Their Bets

In other Vera Therapeutics news, CFO Sean Grant sold 99,828 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $39.61, for a total transaction of $3,954,187.08. Following the completion of the transaction, the chief financial officer now owns 66,337 shares in the company, valued at approximately $2,627,608.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Sean Grant sold 99,828 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $39.61, for a total transaction of $3,954,187.08. Following the transaction, the chief financial officer now directly owns 66,337 shares of the company’s stock, valued at approximately $2,627,608.57. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Maha Katabi sold 81,009 shares of the stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $44.20, for a total transaction of $3,580,597.80. Following the completion of the sale, the director now directly owns 3,547,437 shares in the company, valued at $156,796,715.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 526,551 shares of company stock worth $21,533,345. 21.70% of the stock is owned by insiders.

Vera Therapeutics Stock Performance

VERA stock opened at $38.50 on Friday. The company has a fifty day moving average price of $40.60 and a 200 day moving average price of $32.96. Vera Therapeutics, Inc. has a 12 month low of $7.73 and a 12 month high of $50.78. The company has a current ratio of 28.63, a quick ratio of 28.63 and a debt-to-equity ratio of 0.14.

Vera Therapeutics (NASDAQ:VERAGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). Equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.34 EPS for the current fiscal year.

Vera Therapeutics Profile

(Free Report)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

See Also

Institutional Ownership by Quarter for Vera Therapeutics (NASDAQ:VERA)

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.